Takeda Completes Acquisition of URL Pharma

Takeda's wholly owned subsidiary, Takeda America Holdings, Inc., has completed its acquisition of URL Pharma, Inc. for an upfront payment of $800 million.

Takeda Pharmaceutical Company Limited (Takeda) and its wholly owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. (TPUSA), jointly announced that Takeda's wholly owned subsidiary, Takeda America Holdings, Inc., has completed its acquisition of URL Pharma, Inc. (URL Pharma) for an upfront payment of $800 million.

The deal also includes an agreement for future performance-based contingent earn out payments.

With the completion of the acquisition, TPUSA will begin the integration of URL Pharma and will immediately assume responsibility for the marketing and promotion of Colcrys? (colchicine), URL Pharma's leading product and an important therapy for the treatment and prevention of flares associated with gout. URL Pharma will be managed by Takeda P